• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by TRACON Pharmaceuticals Inc.

    8/30/24 5:05:03 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TCON alert in real time by email
    DEFA14A 1 defa14a_dissolution_meet.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934

     

    Filed by the Registrant 

    Filed by a Party other than the Registrant 

    Check the appropriate box:

     Preliminary Proxy Statement

     Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     Definitive Proxy Statement

     Definitive Additional Materials

     Soliciting Material Pursuant to §240.14a-12

    TRACON Pharmaceuticals, Inc.

    (Name of Registrant as Specified in its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box)

    ☒ No fee required

    ☐ Fee paid previously with preliminary materials

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     


    img120483836_0.jpg 

    Your Vote Counts! TRACON PHARMACEUTICALS, INC. 2024 Special Meeting Vote by October 10, 2024 11:59 PM ET TRACON PHARMACEUTICALS, INC. 124 WASHINGTON ST. FOXBOROUGH, MA 02035 V56032-S96002 You invested in TRACON PHARMACEUTICALS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Special Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held at 11:00 AM Eastern Time on October 11, 2024. Get informed before you vote View the Notice and Proxy Statement and Annual Report on Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to September 27, 2024. To view the voting material(s) online, visit www.ProxyVote.com and have your control number (indicated below) available. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Vote in Person at the Meeting* October 11, 2024 11:00 AM Eastern Time Smartphone users Point your camera here and vote without entering a control number Verdolino & Lowey, 124 Washington St. Foxborough, MA 02035 *Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.

     


     

    img120483836_1.jpg 

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting as described in the more complete proxy materials available to you online. You may view the proxy materials online at www.ProxyVote.com or easily request a paper copy (see reverse side). Please follow the instructions on the reverse side to vote these important matters. We encourage you to access and review all of the important information contained in the proxy materials before voting. Voting Items 1. To consider and vote upon a proposal to approve the liquidation and dissolution of TRACON in accordance with Section 275 of the Delaware General Corporation Law and pursuant to the Plan of Dissolution (the “Plan of Dissolution”) which, if approved, will authorize the Board of Directors of TRACON to liquidate and dissolve the Company in accordance with the Plan of Dissolution. For NOTE: In his discretion, the proxy holder is authorized to vote upon such other business as may properly come before the meeting or any adjournments or postponements thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V56033-S96002

     


    Get the next $TCON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TCON

    DatePrice TargetRatingAnalyst
    2/23/2022$10.00Outperform
    Baird
    More analyst ratings

    $TCON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TRACON Pharmaceuticals Announces it Will Wind Down Operations

    SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (OTCQB:TCON) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors.  The board of directors appointed Craig R. Jalbert, age 62, as the Company's CEO, President, Treasurer and Secretary, and sole member of the board. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. since 1987. For over 30 years he has focused his practice in distressed businesses and has served, and continues to serve, in the capacities of officer and director for numerous firms in

    7/30/24 4:44:46 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform

    The objective response rate by blinded independent central review in the fully enrolled ENVASARC pivotal trial in the 82 evaluable patients is 5% (four responders) and did not meet the primary endpoint of 11% Company will focus on exploring strategic alternatives, that may include a variety of strategic transactions such as a reverse merger, acquisition, sale of all assets, or other strategic transactions leveraging its in-house Product Development Platform of CRO-independent clinical trial execution SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON) today announced the objective response rate (ORR) by blinded independent central review (BICR) in the fully

    7/1/24 9:00:00 AM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients

    Publication Highlights Activity of the Combination of TRC102 and Temodar (Temozolomide) in Patients who Progressed Following Initial Treatment with Surgical Resection, Temodar and External Beam Radiotherapy Consistent with the TRC102 Mechanism of Action, Extended Survival was Demonstrated in Patients with Activation of DNA Damage Response Pathways Prior to TRC102 Treatment SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent Product Development Platform (PDP) to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science c

    6/11/24 8:00:00 AM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TCON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Baird initiated coverage on TRACON Pharmaceuticals with a new price target

    Baird initiated coverage of TRACON Pharmaceuticals with a rating of Outperform and set a new price target of $10.00

    2/23/22 4:50:05 AM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alliance Global Partners initiated coverage on TRACON Pharmaceuticals with a new price target

    Alliance Global Partners initiated coverage of TRACON Pharmaceuticals with a rating of Buy and set a new price target of $13.00

    6/4/21 8:08:23 AM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tracon Pharmaceuticals upgraded by BTIG Research with a new price target

    BTIG Research upgraded Tracon Pharmaceuticals from Neutral to Buy and set a new price target of $14.00

    4/16/21 8:36:58 AM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TCON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Lazar David E.

    3 - Tracon Pharmaceuticals, Inc. (0001394319) (Issuer)

    5/13/24 5:00:43 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Brown Scott B. was granted 3,500 shares, increasing direct ownership by 16% to 25,128 units (SEC Form 4)

    4 - Tracon Pharmaceuticals, Inc. (0001394319) (Issuer)

    3/13/24 5:59:38 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Theuer Charles was granted 7,000 shares, increasing direct ownership by 2% to 406,417 units (SEC Form 4)

    4 - Tracon Pharmaceuticals, Inc. (0001394319) (Issuer)

    3/13/24 5:56:13 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TCON
    SEC Filings

    View All

    SEC Form 15-12G filed by TRACON Pharmaceuticals Inc.

    15-12G - Tracon Pharmaceuticals, Inc. (0001394319) (Filer)

    11/7/24 4:05:49 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by TRACON Pharmaceuticals Inc.

    EFFECT - Tracon Pharmaceuticals, Inc. (0001394319) (Filer)

    11/4/24 12:15:04 AM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by TRACON Pharmaceuticals Inc.

    EFFECT - Tracon Pharmaceuticals, Inc. (0001394319) (Filer)

    11/4/24 12:15:09 AM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TCON
    Leadership Updates

    Live Leadership Updates

    View All

    TRACON Pharmaceuticals Announces it Will Wind Down Operations

    SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (OTCQB:TCON) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors.  The board of directors appointed Craig R. Jalbert, age 62, as the Company's CEO, President, Treasurer and Secretary, and sole member of the board. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. since 1987. For over 30 years he has focused his practice in distressed businesses and has served, and continues to serve, in the capacities of officer and director for numerous firms in

    7/30/24 4:44:46 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TRACON Pharmaceuticals Announces Appointment of Carol Lam to its Board of Directors

    SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing a product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today the appointment of Carol Lam to its Board of Directors. "We are very pleased to welcome Carol to our Board of Directors," said Dr. Charles Theuer, President and Chief Executive Officer of TRACON. "She brings a global perspective on technology development acquired through her extensive experience as deputy General Counsel

    10/13/21 8:00:00 AM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TRACON Pharmaceuticals Announces Appointment of Brenda Marczi, PharmD, as Senior Vice President, Regulatory Affairs, and Granting of Inducement Award

    SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today the appointment of Brenda Marczi, PharmD, as Senior Vice President, Regulatory Affairs, and the granting of an inducement equity award to Dr. Marczi. "We are very pleased to welcome Brenda to the senior management team at TRACON," said Charles Theuer, M.D., Ph.D., President and CEO of TRACON. "

    7/20/21 8:05:00 AM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TCON
    Financials

    Live finance-specific insights

    View All

    TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

    SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (NASDAQ:TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the first quarter ended March 31, 2024. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time. "With ENVASARC fully enrolled we are focused on leveraging our Product Development Platform to generate non-dilutive capital through either an additional license or by replacing a CRO and executi

    5/14/24 4:01:00 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024

    SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (NASDAQ:TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its first quarter 2024 financial and operating results after the close of U.S. financial markets on Tuesday, May 14, 2024. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results. Date:May 14, 2024Time:4:30 pm Eastern Time (1:30 pm Pacific Time)Conference Call:In order t

    5/7/24 4:01:00 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

    SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (NASDAQ:TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the fourth quarter and year ended December 31, 2023. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time. "We are on track to complete enrollment of 80 patients treated with single agent envafolimab in the ongoing pivotal ENVASARC trial later this quarter. We expect to report updated

    3/5/24 4:02:00 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TCON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc.

    SC 13G/A - Tracon Pharmaceuticals, Inc. (0001394319) (Subject)

    11/14/24 8:51:58 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Tracon Pharmaceuticals, Inc. (0001394319) (Subject)

    4/5/24 4:10:26 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Tracon Pharmaceuticals, Inc. (0001394319) (Subject)

    3/19/24 11:20:05 AM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care